# q02 rev 0 - blind solver B (fresh blind-solver, packet solver-2), 2026-10-06

Raw return as received:

I worked this out from the packet: the acquisition closed in fiscal Q2 2026, and that quarter's adjusted free cash flow is not printed anywhere. I derived it as the six-month year-to-date figure minus the first-quarter figure.

answer: **$1.16 billion** (adjusted free cash flow for fiscal Q2 2026, the three months ended March 31, 2026, derived as $1,156.5M)

confidence: high

path:
1. **Completion date.** D03 line 639 (cash-flow footnote): "to finance a portion of the February 2, 2026 acquisition of OneOncology". D05 line 648 gives the same date.
2. **Fiscal quarter boundaries.** D01 line 17: "fiscal year 2026 first quarter ended December 31, 2025". D03 line 15: "fiscal year 2026 second quarter ended March 31, 2026". February 2, 2026 therefore falls in fiscal Q2 2026 (Jan 1 – Mar 31, 2026).
3. **Corroboration that it closed in Q2.**
   - D03 line 214: the $1.1B remeasurement gain was recorded "in the three months ended March 31, 2026".
   - Goodwill and other intangibles were $17.41B at Dec 31, 2025 (D01 line 367) and $22.51B at Mar 31, 2026 (D03 line 576).
   - Cost of acquired companies was $(219.7)M in Q1 (D01 line 407) and $(4,932.0)M for the six months (D03 line 619).
   - The D01 headline "Company Completes Acquisition of OneOncology" appears in the Q1 release dated Feb 4, 2026. That release reports a quarter that had already ended, so it announces the closing after the fact.
4. **Q1 adjusted FCF.** D01 lines 461–469 are "for the three months ended December 31, 2025": operating cash flows $(2,305.2)M; capex $(119.4)M; free cash flows $(2,424.5)M; "(Less) gains from antitrust litigation settlements $(12.2)M"; "Adjusted free cash flows $(2,436.7)M".
5. **Six-month YTD adjusted FCF.** D03 lines 678–686 are "for the six months ended March 31, 2026": operating cash flows $(966.5)M; capex $(285.0)M; free cash flows $(1,251.5)M; antitrust gains $(28.7)M; "Adjusted free cash flows $(1,280.2)M".
6. **Q2 calculation.** −1,280.2 − (−2,436.7) = **+1,156.5M**.
   - A check using the statements in thousands:
     - Operating cash flow: −966,530 − (−2,305,169) = 1,338,639.
     - Capex: −284,994 − (−119,376) = −165,618.
     - Free cash flow: 1,173,021.
     - Antitrust gains: 28,690 − 12,152 = 16,538. This matches D03's Q2 reconciliation line "(16,538)" and footnote 1, "$16.5 million gain ... three months ended March 31, 2026".
     - Adjusted FCF: 1,173,021 − 16,538 = 1,156,483 thousand, which is $1.156B.
   - Rounded to two decimals, that is **$1.16B**.
7. The definition is the same in D01, D03 and D05: "net cash provided by operating activities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures." The company's own reconciliations exclude only the antitrust settlement gains.

minimal_documents: D01 + D03.
- D03 gives the completion date, the quarter boundary and the six-month YTD figure. D01 gives the Q1 figure.
- D05 can replace D03 only for the date. Its FCF reconciliation covers nine months (adjusted $1,142.3M), so it cannot isolate Q2 without D03.
- D02, D04 and D06 cover fiscal 2025 periods only (six months to Mar 31, 2025: $176.0M; nine months to Jun 30, 2025: $92.5M; FY2025: $2,970.8M). None of them mentions OneOncology.

readings:
- **Quarter taken as the one whose release announced the completion (fiscal Q1 2026):** −$2.44B. This conflicts with the stated February 2, 2026 completion date, which falls after Q1 ended on Dec 31, 2025.
- **D03's printed six-month YTD figure taken as the quarter's value:** −$1.28B. This is not a quarterly figure.
- **Unadjusted free cash flow for Q2:** $1.17B ($1,173.0M). This is not the adjusted measure the question asks for.

gaps:
- No release in the packet prints a standalone Q2 FY2026 adjusted FCF figure, so it must be derived by subtracting YTD figures.
- No PDF or layout files exist in this packet (sources are .txt, "method": "text"), so I inspected no original page images. The text tables reconcile arithmetically.
- **Read in full:** D01, D03.
- **D05:** read lines 1–130 and 600–725. The middle tables (131–599) were covered only by searches for "OneOncology" and "free cash flow".
- **D02, D04, D06:** covered by searches plus short reads of their FCF paragraphs (D02:606–613, D04:626–633, D06:676–689).

contaminated: no
